NovoCure's Invested Capital fell 539.05% to $341.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $341.3 million, marking a year-over-year decrease of 539.05%. This contributed to the annual value of $360.2 million for FY2024, which is 6132.59% down from last year.
According to the latest figures from Q3 2025, NovoCure's Invested Capital is $341.3 million, which was down 539.05% from $349.4 million recorded in Q2 2025.
NovoCure's 5-year Invested Capital high stood at $1.0 billion for Q3 2022, and its period low was $341.3 million during Q3 2025.
Over the past 5 years, NovoCure's median Invested Capital value was $957.8 million (recorded in 2021), while the average stood at $778.8 million.
In the last 5 years, NovoCure's Invested Capital soared by 28509.02% in 2021 and then plummeted by 6319.31% in 2024.
Quarter analysis of 5 years shows NovoCure's Invested Capital stood at $972.7 million in 2021, then increased by 3.49% to $1.0 billion in 2022, then dropped by 7.49% to $931.3 million in 2023, then plummeted by 61.33% to $360.2 million in 2024, then dropped by 5.23% to $341.3 million in 2025.
Its Invested Capital was $341.3 million in Q3 2025, compared to $349.4 million in Q2 2025 and $362.0 million in Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value